AR043467A1 - Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson - Google Patents
Combinacion de drogas para la disfuncion motora en la enfermedad de parkinsonInfo
- Publication number
- AR043467A1 AR043467A1 ARP040100686A ARP040100686A AR043467A1 AR 043467 A1 AR043467 A1 AR 043467A1 AR P040100686 A ARP040100686 A AR P040100686A AR P040100686 A ARP040100686 A AR P040100686A AR 043467 A1 AR043467 A1 AR 043467A1
- Authority
- AR
- Argentina
- Prior art keywords
- disease
- parkinson
- dosage form
- receptor antagonist
- nmda receptor
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 5
- 206010061296 Motor dysfunction Diseases 0.000 title abstract 2
- 239000000890 drug combination Substances 0.000 title 1
- 239000002552 dosage form Substances 0.000 abstract 4
- 229940099433 NMDA receptor antagonist Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 abstract 3
- 206010012289 Dementia Diseases 0.000 abstract 2
- 238000013270 controlled release Methods 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 abstract 1
- 206010006100 Bradykinesia Diseases 0.000 abstract 1
- 208000006083 Hypokinesia Diseases 0.000 abstract 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 206010044565 Tremor Diseases 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 abstract 1
- 229960002495 buspirone Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960001653 citalopram Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 229960004688 venlafaxine Drugs 0.000 abstract 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Método, uso y forma de dosificación farmacéutica oral, para tratar la disfunción motora asociada con la enfermedad de Parkinson, con un tratamiento con droga contra la enfermedad de Parkinson, y/o con la demencia asociada a la enfermedad de Parkinson, por ejemplo terapia con levodopa, y/o demencia asociada con la enfermedad de Parkinson. Administración combinada de un antagonista del recepto NMDA y un antidepresivo, por ejemplo la combinación de u amantadita y citalopram o venlafaxina, o un antagonista del receptor NMDA y un agente ansiolítico, por ejemplo amantadita y buspirona o trazadota, para la mejoría de los temblores no deseados, anquinesia, diquinesia o bradiquinesia asociados con uno o mas desordenes o enfermedades diferentes. Las drogas pueden estar incluidas en una sola forma de dosificación. Una realización incluye una forma de dosificación combinada que contiene cada droga en forma de liberación controlada. Otra realización incluye una forma de dosificación combinada que provee una liberación controlada de un antagonista del recetor NMDA y una liberación rápida de un agente neuroactivo luego de la administración a un sujeto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45205503P | 2003-03-05 | 2003-03-05 | |
| US45207703P | 2003-03-05 | 2003-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043467A1 true AR043467A1 (es) | 2005-07-27 |
Family
ID=33135010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100686A AR043467A1 (es) | 2003-03-05 | 2004-03-04 | Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20060063810A1 (es) |
| EP (1) | EP1600156A2 (es) |
| AR (1) | AR043467A1 (es) |
| WO (1) | WO2004087116A2 (es) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| CA2528622C (en) * | 2003-05-27 | 2010-08-03 | Forest Laboratories, Inc. | Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
| WO2005079756A2 (en) * | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| US20190008799A1 (en) * | 2004-11-23 | 2019-01-10 | Adamas Pharma, Llc | Composition for administering an nmda receptor antagonist to a subject |
| MX2007006120A (es) * | 2004-11-23 | 2007-12-07 | Adamas Pharmaceuticals Inc | Metodo y composicion para administrar a un sujeto un antagonista del receptor de nmda. |
| US8389578B2 (en) | 2004-11-24 | 2013-03-05 | Adamas Pharmaceuticals, Inc | Composition and method for treating neurological disease |
| US8252331B2 (en) | 2004-12-03 | 2012-08-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Osmotic device containing amantadine and an osmotic salt |
| AR053986A1 (es) * | 2004-12-03 | 2007-05-30 | Osmotica Pharmaceutical Argent | Dispositivo osmotico que contiene amantadina y una sal osmotica |
| US8574626B2 (en) | 2004-12-03 | 2013-11-05 | Osmotica Kereskedelmi és Szolgáltató KFT | Osmotic device containing amantadine and an osmotic salt |
| NZ555693A (en) | 2004-12-27 | 2010-10-29 | Eisai R&D Man Co Ltd | Matrix type sustained-release preparation containing donepezil |
| US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
| CA2595607C (en) * | 2005-01-25 | 2014-07-15 | Epix Delaware, Inc. | Substituted arylamine compounds and their use as 5-ht6 modulators |
| PL2982372T3 (pl) | 2005-04-05 | 2020-12-28 | Yale University | Środki modulujące stężenie glutaminianu stosowane w leczeniu zaburzeń psychicznych |
| EP1874282B1 (en) | 2005-04-06 | 2010-09-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for treatment of cns disorders |
| ATE489079T1 (de) | 2005-12-29 | 2010-12-15 | Osmotica Kereskedelmi Es Szolgaltata Kft | Mehrschichtige tablette mit dreifacher freisetzungskombination |
| GB0623897D0 (en) * | 2006-11-30 | 2007-01-10 | Pliva Istrazivanje I Razvoj D | Pharmaceutical composition of memantine |
| CA2775091A1 (en) * | 2009-08-05 | 2011-02-10 | Lupin Limited | Controlled release pharmaceutical compositions of milnacipran |
| BR112012013487A2 (pt) | 2009-12-02 | 2017-10-03 | Adamas Pharmaceuticals Inc | Composições de amantadina e métodos de uso |
| WO2011107922A2 (en) * | 2010-03-04 | 2011-09-09 | Ranbaxy Laboratories Limited | Extended release composition of milnacipran |
| WO2012083128A2 (en) * | 2010-12-16 | 2012-06-21 | The Mclean Hospital Corporation | Prevention and treatment of diseases characterized by mesencephalic dopaminergic neuron cell death |
| EP2661307A4 (en) | 2011-01-03 | 2014-08-06 | Univ California | HIGH-DENSITY EPIDURAL STIMULATION TO FACILITATE MOVEMENTS, ATTACHMENTS, ARBITRARY MOVEMENTS AND RECOVERY OF AUTONOMIC, SEXUAL, VASOMOTORIC AND COGNITIVE FUNCTIONS AFTER NEUROLOGICAL INJURIES |
| CN103608067A (zh) | 2011-01-21 | 2014-02-26 | 加利福尼亚理工学院 | 脊髓刺激法的聚对二甲苯基微电极阵列植入 |
| WO2012110912A1 (en) * | 2011-02-17 | 2012-08-23 | Lupin Limited | Sustained release composition of memantine |
| BR112013024491A2 (pt) | 2011-03-24 | 2017-03-21 | California Inst Of Techn | neuroestimulador. |
| AU2012334926B2 (en) | 2011-11-11 | 2017-07-13 | The Regents Of The University Of California | Transcutaneous spinal cord stimulation: noninvasive tool for activation of locomotor circuitry |
| CN106913955B (zh) | 2011-11-11 | 2019-09-17 | 神经赋能科技公司 | 非侵入神经调节系统 |
| US10092750B2 (en) | 2011-11-11 | 2018-10-09 | Neuroenabling Technologies, Inc. | Transcutaneous neuromodulation system and methods of using same |
| CN102755310B (zh) * | 2012-07-26 | 2016-06-15 | 温天文 | 一种含有左旋多巴的组合物药物制剂 |
| AU2014228794B2 (en) | 2013-03-15 | 2019-04-18 | The Regents Of The University Of California | Multi-site transcutaneous electrical stimulation of the spinal cord for facilitation of locomotion |
| WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
| AU2014324660A1 (en) | 2013-09-27 | 2016-04-21 | The Regents Of The University Of California | Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects |
| WO2015106286A1 (en) | 2014-01-13 | 2015-07-16 | California Institute Of Technology | Neuromodulation systems and methods of using same |
| EP3183028A4 (en) | 2014-08-21 | 2018-05-02 | The Regents of the University of California | Regulation of autonomic control of bladder voiding after a complete spinal cord injury |
| US10773074B2 (en) | 2014-08-27 | 2020-09-15 | The Regents Of The University Of California | Multi-electrode array for spinal cord epidural stimulation |
| US11298533B2 (en) | 2015-08-26 | 2022-04-12 | The Regents Of The University Of California | Concerted use of noninvasive neuromodulation device with exoskeleton to enable voluntary movement and greater muscle activation when stepping in a chronically paralyzed subject |
| US11097122B2 (en) | 2015-11-04 | 2021-08-24 | The Regents Of The University Of California | Magnetic stimulation of the spinal cord to restore control of bladder and/or bowel |
| US11235154B2 (en) | 2017-02-17 | 2022-02-01 | The University Of British Columbia | Apparatus and methods for maintaining physiological functions |
| US12434068B2 (en) | 2017-05-23 | 2025-10-07 | The Regents Of The University Of California | Accessing spinal networks to address sexual dysfunction |
| DE20168827T1 (de) | 2017-06-30 | 2021-01-21 | Gtx Medical B.V. | System zur neuromodulierung |
| IL272834B2 (en) | 2017-08-24 | 2024-08-01 | Adamas Pharma Llc | Amantadine compositions, preparations thereof, and methods of use |
| WO2019110400A1 (en) | 2017-12-05 | 2019-06-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | A system for planning and/or providing neuromodulation |
| US12357828B2 (en) | 2017-12-05 | 2025-07-15 | Ecole Polytechnique Federale De Lausanne (Epfl) | System for planning and/or providing neuromodulation |
| US10213394B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
| US20190247331A1 (en) | 2018-02-15 | 2019-08-15 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
| US10213393B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság | Composition and method for treating neurological disease |
| US12478777B2 (en) | 2018-08-23 | 2025-11-25 | The Regents Of The University Of California | Non-invasive spinal cord stimulation for nerve root palsy, cauda equina syndrome, and restoration of upper extremity function |
| EP3653260A1 (en) | 2018-11-13 | 2020-05-20 | GTX medical B.V. | Sensor in clothing of limbs or footwear |
| DE18205821T1 (de) | 2018-11-13 | 2020-12-24 | Gtx Medical B.V. | Steuerungssystem zur bewegungsrekonstruktion und/oder wiederherstellung für einen patienten |
| EP3695878B1 (en) | 2019-02-12 | 2023-04-19 | ONWARD Medical N.V. | A system for neuromodulation |
| EP3827871A1 (en) | 2019-11-27 | 2021-06-02 | ONWARD Medical B.V. | Neuromodulation system |
| EP3827875B1 (en) | 2019-11-27 | 2023-07-05 | ONWARD Medical N.V. | Neuromodulation system |
| WO2023201070A1 (en) * | 2022-04-14 | 2023-10-19 | Ohio State Innovation Foundation | Methods and systems for identifying therapeutic agents for improving brain function |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4388582A (en) * | 1978-05-31 | 1983-06-14 | Black & Decker Inc. | Apparatus and method for charging batteries |
| US5268630A (en) * | 1992-05-04 | 1993-12-07 | Black & Decker Inc. | Method and apparatus for varying the sample rate of a fast battery charger |
| JP2001527554A (ja) * | 1997-05-07 | 2001-12-25 | アルゴス ファーマシューティカル コーポレーション | 抗うつ薬とｎｍｄａレセプター拮抗薬とを組み合わせる神経障害痛の治療用組成物及び治療方法 |
| US6175211B1 (en) * | 1999-04-15 | 2001-01-16 | Black & Decker Inc. | Battery pack with identification device |
| AU2003298664A1 (en) * | 2002-11-20 | 2004-06-15 | Cypress Bioscience, Inc. | Treatment of cognitive dysfunctions' |
| WO2004056335A2 (es) * | 2002-12-23 | 2004-07-08 | Osmotica Costa Rica Sociedad Anonima | Dispositivo de liberación que contiene venlafaxina y memantina |
-
2004
- 2004-03-04 AR ARP040100686A patent/AR043467A1/es not_active Application Discontinuation
- 2004-03-05 EP EP04738449A patent/EP1600156A2/en not_active Withdrawn
- 2004-03-05 WO PCT/CR2004/000003 patent/WO2004087116A2/es not_active Ceased
-
2005
- 2005-08-30 US US11/215,797 patent/US20060063810A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004087116A3 (es) | 2004-12-16 |
| EP1600156A2 (en) | 2005-11-30 |
| US20060063810A1 (en) | 2006-03-23 |
| WO2004087116A2 (es) | 2004-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR043467A1 (es) | Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson | |
| Kadriu et al. | Glutamatergic neurotransmission: pathway to developing novel rapid-acting antidepressant treatments | |
| Pollack et al. | Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial | |
| AR041725A1 (es) | Prevencion, tratamiento de la enfermedad sinucleinopatica y composicion farmacologica | |
| Steiner et al. | Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder | |
| PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
| AR039744A1 (es) | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada | |
| AR045972A1 (es) | Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas | |
| PE20160195A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
| BRPI0407485A (pt) | utilização de anticorpos anti-receptores de factor crescimento i semelhantes aos anti-insulina | |
| UY29377A1 (es) | Nuevas formilaciones líquidas de rotavirus, su preparación y sus usos. | |
| EP2248519A3 (en) | Non-mucoadhesive film dosage forms | |
| BRPI0418029A (pt) | formulação de anticorpos cd40 e métodos | |
| BR0311701A (pt) | Formulação de dosagem multiparticulada com liberação controlada de lamotrigina, composição farmacêutica, processo para a preparação de uma composição farmacêutica de lamotrigina, método para a redução da flutuação no pico e no depósito da concentração da droga no plasma do sangue de um paciente, método para melhorar a complacência de um paciente pela redução da frequência de dosagem para uma vez por dia, método para a ministração mais segura de lamotrigina, método para proporcionar uma concentração terapêutica de plasma de sangue de lamotrigina e uso da formulação | |
| BRPI0414347A (pt) | associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| TW200738228A (en) | Neramexane modified release matrix tablet | |
| BRPI0416275A (pt) | métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada | |
| Eser et al. | Agomelatine: the evidence for its place in the treatment of depression | |
| Keller et al. | The role of mirtazapine in the pharmacotherapy of depression | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| AR027394A1 (es) | Uso de mirtazapina para el tratamiento de trastornos del sueno | |
| AR018376A1 (es) | Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento | |
| UY28216A1 (es) | Combinacion de drogas para la disfunción motora en la enfermedad de parkinson | |
| Yanik | Spontaneous orgasm started with venlafaxine and continued with citalopram |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure | ||
| FB | Suspension of granting procedure | ||
| FA | Abandonment or withdrawal |